Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
CTI BioPharma Corp. Stock Forecast NASDAQ:CTIC
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-03-02 | 2.67% | JMP Securities | $4.00 $5.00 | Maintains | Market Outperform |
| 2022-03-02 | 64.27% | Needham | $5.00 $8.00 | Maintains | Buy |
| 2021-12-01 | 2.67% | Needham | $6.00 $5.00 | Maintains | Buy |
| 2021-08-09 | 43.74% | BTIG | $7.00 | Initiates Coverage On | Buy |
| 2021-05-06 | 12.94% | Stifel | $5.50 | Initiates Coverage On | Buy |
| 2020-10-23 | 43.74% | Brookline Capital | $7.00 | Initiates Coverage On | Buy |
| 2020-09-30 | 23.2% | Needham | $3.50 $6.00 | Maintains | Buy |
CTIC Stock Trend
The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled.
Given the current short-term trend, the stock is expected to rise 34.58% during the next 3 months and, with a 90% probability hold a price between $4.47 and $7.98 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-23 | $3.35 | $4.65 | $5.95 |
| 2022-05-24 | $3.37 | $4.68 | $5.98 |
| 2022-05-25 | $3.40 | $4.70 | $6.00 |
| 2022-05-26 | $3.42 | $4.73 | $6.03 |
| 2022-05-27 | $3.45 | $4.75 | $6.05 |
| 2022-05-31 | $3.47 | $4.78 | $6.08 |
| 2022-06-01 | $3.50 | $4.80 | $6.10 |
| 2022-06-02 | $3.52 | $4.83 | $6.13 |
| 2022-06-03 | $3.55 | $4.85 | $6.15 |
| 2022-06-06 | $3.57 | $4.88 | $6.18 |
| 2022-06-07 | $3.60 | $4.90 | $6.20 |
| 2022-06-08 | $3.62 | $4.93 | $6.23 |
| 2022-06-09 | $3.65 | $4.95 | $6.25 |
| 2022-06-10 | $3.67 | $4.98 | $6.28 |
| 2022-06-13 | $3.70 | $5.00 | $6.30 |
| 2022-06-14 | $3.72 | $5.03 | $6.33 |
| 2022-06-15 | $3.75 | $5.05 | $6.35 |
| 2022-06-16 | $3.77 | $5.08 | $6.38 |
| 2022-06-17 | $3.80 | $5.10 | $6.40 |
| 2022-06-21 | $3.82 | $5.13 | $6.43 |
| 2022-06-22 | $3.85 | $5.15 | $6.45 |
| 2022-06-23 | $3.87 | $5.18 | $6.48 |
| 2022-06-24 | $3.90 | $5.20 | $6.50 |
| 2022-06-27 | $3.92 | $5.23 | $6.53 |
| 2022-06-28 | $3.95 | $5.25 | $6.55 |
| 2022-06-29 | $3.97 | $5.28 | $6.58 |
| 2022-06-30 | $4.00 | $5.30 | $6.60 |
| 2022-07-01 | $4.02 | $5.33 | $6.63 |
| 2022-07-05 | $4.05 | $5.35 | $6.65 |
| 2022-07-06 | $4.07 | $5.38 | $6.68 |
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also devel... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
